股票骗局有哪些-中信证券app-【东方资本】,a股交易t 几,t0开通条件,专业线上配资

<tbody id="anr5x"><nav id="anr5x"></nav></tbody>

<strike id="anr5x"></strike>

<menu id="anr5x"></menu>

科學文獻

我們與學術機構開展合作研究，以評估我們的管線產品。以下是發表的相關文獻。

年：

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen […]

Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database

Binod Dhakal, Jinghua He, Jordan M Schecter, William De […]

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, Jo?o Mendes,H […]

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Simon J Harrison, Cyrille Touzeau, Nicolas Kint, Kather […]

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial

Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Mag […]

本網站使用Cookies來改善您的整體體驗，讓您下次訪問網站時更加輕松快捷，為您帶來更好的服務。具體內容請參閱隱私政策 Cookie政策。

<dl id="ilokg"><optgroup id="ilokg"></optgroup></dl><dd id="ilokg"><nav id="ilokg"><center id="ilokg"></center></nav></dd>